Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Metastatic Soft Tissue Sarcoma: early-phase trial registry
7 of 13 indexed Metastatic Soft Tissue Sarcoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,315 of 28,707 conditions by registered trial count.
13 US clinical trials · 7 currently recruiting · #1,315 of 28,707 conditions by registered trial count
Metastatic Soft Tissue Sarcoma: 13 US clinical trials tracked, 7 recruiting.
Metastatic Soft Tissue Sarcoma is the subject of 13 registered US clinical trials on ClinicalTrials.gov, 7 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 13 in Phase 1-2 (earlier-stage). The most active sponsor is Washington University School of Medicine, running 2 of these trials.
Enrollment posture brief
Registry condition metastatic-soft-tissue-sarcoma
OPEN 7 | RECR 54% | LATE 0 | EARLY 13 | RANK #1315 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Advanced Renal Cell Carcinoma (54% recruiting · 13 trials)
Metastatic Soft Tissue Sarcoma lists 7 open slots (54% of 13 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Metastatic Soft Tissue Sarcoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Metastatic Soft Tissue Sarcoma is recruiting above its size-band peers.
7 of 13 indexed trials (53.8%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Metastatic Soft Tissue Sarcoma research.
Washington University School of Medicine accounts for 2 of 13 trials (15.4%). 11 distinct sponsors appear on at least one study for this condition label.
-
Most Metastatic Soft Tissue Sarcoma trials plan to enrol fewer than 100 people.
Median target enrolment is 74 among the 13 trials that report a genuine target (sentinel values excluded). 8 of those (61.5%) plan for fewer than 100 participants.
-
Metastatic Soft Tissue Sarcoma research is mostly interventional.
13 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
13 total, page 1 of 1
First-in-Human Study of ADCE-D01 in Soft Tissue Sarcoma
Adcendo ApS
NCT06797999
SAINT:Trabectedin, Ipilimumab and Nivolumab for Previously Treated Advanced Soft Tissue Sarcoma
Sarcoma Oncology Research Center
NCT03138161
Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases
Roswell Park Cancer Institute
NCT03965234
Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma
National Cancer Institute (NCI)
NCT06498648
Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas
University of Colorado, Denver
NCT04028063
T Cell Membrane-Anchored Tumor-Targeted IL12 -Modified TIL Cell Therapy (attIL12-TIL) for Advanced/Metastatic Soft Tissue and Bone Sarcoma Patients.
M.D. Anderson Cancer Center
NCT06474676
Zanzalintinib in Combination With Ipilimumab and Nivolumab in Patients With Metastatic Soft Tissue Sarcoma
Washington University School of Medicine
NCT06968988
Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors
M.D. Anderson Cancer Center
NCT05075993
Cabozantinib Combined With PD-1 and CTLA-4 Inhibition in Metastatic Soft Tissue Sarcoma
Washington University School of Medicine
NCT04551430
Cabozantinib and Temozolomide for the Treatment of Unresectable or Metastatic Leiomyosarcoma or Other Soft Tissue Sarcoma
City of Hope Medical Center
NCT04200443
Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma
National Cancer Institute LAO
NCT05836571
Lurbinectedin + Doxorubicin In Leiomyosarcoma
Massachusetts General Hospital
NCT05099666
Sarcoma Study of MORAb-004 Utilization: Research and Clinical Evaluation
Morphotek
NCT01574716
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 8 |
| Phase 2 | 5 |
Top Sponsors
Named interventions
Most-linked intervention names on Metastatic Soft Tissue Sarcoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Metastatic Soft Tissue Sarcoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Metastatic Soft Tissue Sarcoma page
13 registered trials, 7 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 7 Metastatic Soft Tissue Sarcoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Washington University School of Medicine sponsors the most Metastatic Soft Tissue Sarcoma trials on record, review their full trial history before evaluating a specific study. See Washington University School of Medicine's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Metastatic Soft Tissue Sarcoma condition card totals 13 registered trials; most-linked intervention Cabozantinib; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.